Scientists are actively investigating a potential metabolic protocol involving the combined usage of Semaglutide, a dual GIP/GLP-1 receptor agonist; Retatrutide, an experimental triple GIP/GLP-1/GCG receptor agonist; https://biopeptidestore.com/